Satisfaction and knowledge among patients with HIV after switching from tenofovir to tenofovir alafenamide in regimens containing emtricitabine and rilpivirine
Abstract
Introduction: Satisfaction and knowledge among patients with HIV after switching from tenofovir to tenofovir/alafenamide remain unexplored. Given that both parameters are associated with better health outcomes it is relevant to measure them in patients during routine clinical practice.
Objective: To evaluate the degree of knowledge and satisfaction in patients who had their antiretroviral regimen switched from rilpivirine (RPV)/emtricitabine (FTC)/TDF to RPV/FTC/TAF.
Materials and methods: We conducted a prospective study in a third-level hospital between September, 2018, and November, 2018. We included patients who had previously been treated with RPV/FTC/TDF and collected their RPV/FTC/TAF treatment in the second visit. A 5-point Likert-type agreement/disagreement scale was used to assess satisfaction and knowledge regarding the medication switch.
Results: We included 116 patients in the study of whom 75% were satisfied and 64% had a high-level of knowledge. Young patients were less satisfied with the way in which the change was explained (p=0.0487). Concerning the new medication, the patients were better informed about its renal (85% of them) and bone benefits (82%) than about its adverse effects on the lipid profile (40%).
Conclusions: The patients were generally satisfied with the change in medication and well nformed about the dosage and advantages of TAF over TDF, but less well informed about the possible adverse effects of TAF.
Downloads
References
Rodger AJ, Lodwick R, Schechter M, Deeks S, Amin J, Gilson R, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials ompared with the general population. AIDS. 2013;27:973-9. https://doi.org/10.1097/QAD.0b013e32835cae9c
Casado JL. Renal and bone toxicity with the use of tenofovir: Understanding at the end. AIDS Rev. 2016;18:59-68.
De Clercq E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem Pharmacol. 2016;119:1-7. https://doi.org/10.1016/j.bcp.2016.04.015
Gallant JE, Daar ES, Raffi F, Brinson C, Ruane P, DeJesus E, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: A randomised, double-blind, active-controlled phase 3 trial. Lancet HIV. 2016;3:e158-65. https://doi.org/10.1016/S2352-3018(16)00024-2
Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: Two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385:2606-15. https://doi.org/10.1016/S0140-6736(15)60616-X
Hagins D, Orkin C, Daar ES, Mills A, Brinson C, DeJesus E, et al. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials. HIV Med. 2018;19:724-33. https://doi.org/10.1111/hiv.12664
Lee SS, Havens JP, Sayles HR, O’Neill JL, Podany AT, Swindells S, et al. A pharmacist-led medication switch protocol in an academic HIV clinic: Patient knowledge and satisfaction. BMC Infect Dis. 2018;18:310. https://doi.org/10.1186/s12879-018-3226-2
Dang BN, Westbrook RA, Black WC, Rodríguez-Barradas MC, Giordano TP. Examining the link between patient satisfaction and adherence to HIV care: A structural equation model. PloS One. 2013;8:e54729. https://doi.org/10.1371/journal.pone.0054729
McNicholl IR, Gandhi M, Hare CB, Greene M, Pierluissi E. A pharmacist-led program to evaluate and reduce polypharmacy and potentially inappropriate prescribing in older HIV positive patients. Pharmacotherapy. 2017;37:1498-506. https://doi.org/10.1002/phar.2043
Schafer JJ, Gill TK, Sherman EM, McNicholl IR. ASHP Guidelines on pharmacist involvement in HIV care. Am J Health Syst Pharm. 2016;73:468-94. https://doi.org/10.2146/ajhp150623
Bowling A, Rowe G, Lambert N, Waddington M, Mahtani KR, Kenten C, et al. The measurement of patients’ expectations for health care: A review and psychometric testing of a measure of patients’ expectations. Health Technol Assess. 2012;16:1-509. https://doi.org/10.3310/hta16300
Cantillana-Suárez M de G, Manzano-García M, Robustillo-Cortés M de LA, Morillo-Verdugo R. Evaluation of HIV+ patients experience with pharmaceutical care based on AMOmethodology. Farm Hosp. 2018;42:200-3. https://doi.org/10.7399/fh.10947
Umeokonkwo CD, Aniebue PN, Onoka CA, Agu AP, Sufiyan MB, Ogbonnaya L. Patients’ satisfaction with HIV and AIDS care in Anambra State, Nigeria. PLoS One. 2018;13:e0206499. https://doi.org/10.1371/journal.pone.0206499
Clay PG, Yuet WC, Moecklinghoff CH, Duchesne I, Tronczyński KL, Shah S, et al. A metaanalysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV. AIDS Res Ther. 2018;15:17. https://doi.org/10.1186/s12981-018-0204-0
Murray M, Pulido F, Mills A, Ramgopal M, LeBlanc R, Jaeger H, et al. Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study. HIV Res Clin Pract. 2019:20:111-122. https://doi.org/10.1080/25787489.2019.1661696
George EC, Bucciardini R, Richert L, Dedes N, Fragola V, Nieuwkerk P, et al. Patient reported outcomes in first-line antiretroviral therapy: Results from NEAT001/ANRS143 trial comparing darunavir/ritonavir in combination with tenofovir/emtricitabine or raltegravir. J Acquir Immune Defic Syndr. 2018;79:519-26. https://doi.org/10.1097/QAI.0000000000001844
Moreno-Montoya J, Barragán AM, Martínez M, Rodríguez A, González AC. Calidad de vida y percepción de apoyo social en personas con HIV en Bogotá, Colombia. Biomédica. 2018;38:577-85. https://doi.org/10.7705/biomedica.v38i4.3819
Náfrádi L, Nakamoto K, Schulz PJ. Is patient empowerment the key to promote adherence? A systematic review of the relationship between self-efficacy, health locus of control and medication adherence. PloS One. 2017;12:e0186458. https://doi.org/10.1371/journal.pone.0186458
Jones D, Cook R, Rodríguez A, Waldrop-Valverde D. Personal HIV knowledge, appointment adherence and HIV outcomes. AIDS Behav. 2013;17:242-9. https://doi.org/10.1007/s10461-012-0367-y
Kusch MK, Haefeli WE, Seidling HM. How to meet patients’ individual needs for drug information - a scoping review. Patient Prefer Adherence. 2018;12:2339-55. https://doi.org/10.2147/PPA.S173651
Dekkers CC, Westerink J, Hoepelman AI, Arends JE. Overcoming obstacles in lipid lowering therapy in patients with HIV - a systematic review of current evidence. AIDS Rev. 2018;20:205-19. https://doi.org/10.24875/AIDSRev.18000016
Jose J, AlHajri L. Potential negative impact of informing patients about medication side effects: A systematic review. Int J Clin Pharm. 2018;40:806-22. https://doi.org/10.1007/s11096-018-0716-7
Some similar items:
- Mauricio Beltrán, María Cristina Navas, María Patricia Arbeláez, Jorge Donado, Sergio Jaramillo, Fernando De la Hoz, Cecilia Estrada, Lucía del Pilar Cortés, Amalia de Maldonado, Gloria Rey, Seroprevalence of hepatitis B virus and human immunodeficiency virus infection in a population of multiply-transfused patients in Colombia , Biomedica: Vol. 29 No. 2 (2009)
- Daniel Eduardo Henao, Fabián Alberto Jaimes, Evidence-based medicine: an epistemological approach , Biomedica: Vol. 29 No. 1 (2009)
- María Patricia Arbeláez, Alexánder Arbeláez, Rubén Darío Gómez, Carlos Rojas, Lázaro Vélez, Sonia Luz Arias, Jorge Nagles, Luz Marina Peláez, Gloria Betancourt, Gloria Velásquez, Effectiveness of prophylaxis against tuberculosis in patients infected with HIV , Biomedica: Vol. 27 No. 4 (2007)
- María Teresa Rugeles, Paula A. Velilla, Carlos J. Montoya, Mechanisms of human natural resistance to HIV: A summary of ten years of research in the Colombian population , Biomedica: Vol. 31 No. 2 (2011)
- Jaiberth Cardona-Arias, Luz Peláez-Vanegas, Juan López-Saldarriaga, Marcela Duque-Molina, Oscar Leal-Álvarez, Health related quality of life in adults with HIV/AIDS in Colombia , Biomedica: Vol. 31 No. 4 (2011)
- Sandra Rincón, Adriana Celis, Leticia Sopó, Adriana Motta, María Caridad Cepero de García, Malassezia yeast species isolated from patients with dermatologic lesions. , Biomedica: Vol. 25 No. 2 (2005)
- Adriana M. Celis, María Caridad Cepero de García, Genetic polymorphism of Malassezia spp. yeast isolates from individuals with and without dermatological lesions. , Biomedica: Vol. 25 No. 4 (2005)
- Zulbey Rivero-Rodríguez, Amparo Hernández, Ángela Bracho, Solneumar Salazar, Rafael Villalobos, Prevalence of intestinal microsporidia and other intestinal parasites in HIV positive patients of Maracaibo, Venezuela , Biomedica: Vol. 33 No. 4 (2013)
- Liliana Villa, Iván Mauricio Trompa, Fernando Nicolás Montes, Joaquín Guillermo Gómez, Carlos Andrés Restrepo, Analysis of mortality caused by tuberculosis in Medellín, Colombia, 2012 , Biomedica: Vol. 34 No. 3 (2014)
- Leonardo F. Jurado, Martha I. Murcia, Patricia Hidalgo, John E. Leguizamón, Lorena R. González, Phenotypic and genotypic diagnosis of bone and miliary tuberculosis in an HIV+ patient in Bogotá, Colombia , Biomedica: Vol. 35 No. 1 (2015)
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
